ObsEva SA (OBSV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
48
About the Report
About the Report
Summary
ObsEva SA (ObsEva) is a clinical-stage biopharmaceutical company that develops and commercializes drugs for women's reproductive health and pregnancy. The company's product portfolio comprises pipeline products which is being developed to control preterm labor by reducing inflammation, decreasing uterine contractions and preventing cervical changes and membrane ruptures; for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women and to decrease contractions, improve uterine blood flow and enhance the receptivity of the endometrium to embryo implantation. ObsEva is headquartered in Geneva, Switzerland.
ObsEva SA (OBSV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
ObsEva SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ObsEva SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ObsEva SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ObsEva SA, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
ObsEva Raises USD59 Million in Series B Financing Round 11
ObsEva Raises USD 34.8 Million In Series A Financing 13
Licensing Agreements 14
ObsEva Enters into Licensing Agreement with Kissei Pharma 14
ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 15
ObsEva Enters Into Licensing Agreement With Merck Serono 16
Equity Offering 17
ObsEva Prices Public Offering of Shares for USD73.1 Million 17
ObsEva Raises USD60 Million in Private Placement of Shares and Warrants 19
ObsEva Completes IPO of Shares for USD96.75 million 21
ObsEva SA-Key Competitors 23
ObsEva SA-Key Employees 24
ObsEva SA-Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 08, 2018: ObsEva reports third quarter 2018 financial results and provides business update 26
Aug 08, 2018: ObsEva reports second quarter 2018 financial results and provides business update 28
May 16, 2018: ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update 30
Mar 09, 2018: ObsEva Reports Fourth Quarter And Year-End 2017 Financial Results And Provides Business Update 31
Nov 14, 2017: ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update 33
Aug 15, 2017: ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update 34
May 18, 2017: ObsEva Reports First Quarter 2017 Financial Results and Business Update 35
Corporate Communications 36
Jul 25, 2018: ObsEva Expands Executive Team Hiring a Chief Commercial Officer 36
Jul 13, 2018: ObsEva to start trading on the SIX Swiss Exchange 37
Jun 01, 2018: ObsEva to Seek SIX Share Listing 38
Feb 01, 2018: Dr. Ernest Loumaye, CEO of ObsEva returns to work following a personal leave for medical reasons 39
Jan 17, 2017: ObsEva Expands Leadership Team and Board of Directors with Industry Veterans 40
Product News 41
06/29/2017: ObsEva Announces To Present on OBE022 at ESHRE 2017 Annual Meeting 41
03/17/2017: ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor 42
03/01/2018: ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting 43
Clinical Trials 44
Dec 05, 2017: ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor 44
Sep 11, 2017: ObsEva Announces Presentation Related to its PGF2a Receptor Antagonist at ACCP 2017 Annual Meeting 45
May 18, 2017: ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022 46
Jan 13, 2017: ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
List of Figure
List of Figures
ObsEva SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ObsEva SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
List of Table
List of Tables
ObsEva SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ObsEva SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ObsEva SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ObsEva SA, Deals By Therapy Area, 2012 to YTD 2018 9
ObsEva SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ObsEva Raises USD59 Million in Series B Financing Round 11
ObsEva Raises USD 34.8 Million In Series A Financing 13
ObsEva Enters into Licensing Agreement with Kissei Pharma 14
ObsEva Enters into Licensing Agreement with Merck Serono for OBE022 15
ObsEva Enters Into Licensing Agreement With Merck Serono 16
ObsEva Prices Public Offering of Shares for USD73.1 Million 17
ObsEva Raises USD60 Million in Private Placement of Shares and Warrants 19
ObsEva Completes IPO of Shares for USD96.75 million 21
ObsEva SA, Key Competitors 23
ObsEva SA, Key Employees 24
ObsEva SA, Subsidiaries 25
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.